Drug Class
antipsychotics

Available Guidelines

  1. DPWG Guideline for aripiprazole and CYP2D6
  2. DPWG Guideline for clozapine and CYP2D6
  3. DPWG Guideline for haloperidol and CYP2D6
  4. DPWG Guideline for olanzapine and CYP2D6
  5. DPWG Guideline for risperidone and CYP2D6

last updated 02/07/2014

1. DPWG Guideline for aripiprazole and CYP2D6

Summary

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.

There's more of this guideline. Read more.





last updated 08/25/2016

5. DPWG Guideline for risperidone and CYP2D6

Summary

Select an alternative drug or be extra alert to adverse drug events (ADR) for patients who are CYP2D6 poor metabolizers, intermediate metabolizers, or ultrarapid metabolizers with risperidone. Adjust risperidone dose to clinical response.

There's more of this guideline. Read more.



Annotated Labels

  1. FDA Label for aripiprazole and CYP2D6
  2. FDA Label for chlorpromazine
  3. FDA Label for clozapine and CYP2D6
  4. FDA Label for droperidol
  5. FDA Label for fluphenazine
  6. FDA Label for haloperidol
  7. FDA Label for mesoridazine
  8. FDA Label for paliperidone
  9. FDA Label for perphenazine and CYP2D6
  10. FDA Label for pimozide and CYP2D6
  11. FDA Label for quetiapine
  12. FDA Label for risperidone and CYP2D6
  13. FDA Label for thioridazine and CYP2D6
  14. FDA Label for ziprasidone
  15. FDA Label for fluoxetine,olanzapine and CYP2D6
  16. EMA Label for aripiprazole and CYP2D6,CYP3A4
  17. EMA Label for olanzapine and CYP1A2,CYP2D6
  18. HCSC Label for aripiprazole and CYP2D6
  19. HCSC Label for risperidone and CYP2D6




















PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Clinical Annotation for rs1800497 (ANKK1, DRD2), antipsychotics, clozapine, olanzapine, risperidone, Hyperprolactinemia, tardive dyskinesia and Weight gain (level 2B Toxicity/ADR)

Level of Evidence
Level 2B
Type
Toxicity/ADR
Variant
rs1800497
Genes
ANKK1, DRD2
Phenotypes
Hyperprolactinemia, tardive dyskinesia, Weight gain
OMB Race
Mixed Population
Race Notes
Whites, Mixed, one has note that association is more significant in males and caucasians

To see the rest of this clinical annotation please register or sign in.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for antipsychotics

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA ABCB1 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available CA VA CYP2D6 *3 N/A N/A N/A
No VIP available CA VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA CYP2D6 *5 N/A N/A N/A
No VIP available CA VA CYP2D6 *6 N/A N/A N/A
No VIP available CA VA CYP2D6 *7 N/A N/A N/A
No VIP available CA VA CYP2D6 *10 N/A N/A N/A
No VIP available CA VA CYP2D6 *14 N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizers and intermediate metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizers N/A N/A N/A
No VIP available CA VA
rs10042486 NC_000005.10:g.63965502C>T, NC_000005.9:g.63261329C>T, NG_032816.1:g.1791G>A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1010978 NC_000023.10:g.129479460T>C, NC_000023.11:g.130345486T>C, NG_012850.1:g.10414T>C, NM_001282195.1:c.169+211T>C, NM_001282196.1:c.160+211T>C, NM_001282197.1:c.160+211T>C, NM_001282198.1:c.64+211T>C, NM_003951.2:c.169+211T>C, NM_022810.1:c.160+211T>C, NR_104107.1:n.183+211T>C, XM_005262485.1:c.253+211T>C, XM_005262486.1:c.169+211T>C, XM_005262487.1:c.160+211T>C, XM_005262488.1:c.64+211T>C, XM_005262489.1:c.15-3765T>C, XM_005262489.3:c.15-3765T>C, XM_011531402.1:c.196+211T>C, XM_011531403.1:c.64+211T>C, XM_011531404.1:c.160+211T>C, XM_011531405.1:c.64+211T>C, XR_244526.1:n.323+211T>C, XR_244527.1:n.323+211T>C, rs17268202
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1012650 NC_000016.10:g.26500225C>T, NC_000016.9:g.26511546C>T, rs111192057, rs59648671
C > T
SNP
No VIP available No Clinical Annotations available VA
rs10211524 NC_000002.11:g.65208074G>A, NC_000002.12:g.64980940G>A, rs58531800
G > A
SNP
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available CA VA
rs10490162 NC_000002.11:g.51247657T>C, NC_000002.12:g.51020519T>C, NG_011878.1:g.17018A>G, NM_001135659.1:c.871+5852A>G, NM_004801.4:c.772+6983A>G, XM_005264642.1:c.772+6983A>G, XM_005264642.2:c.772+6983A>G, XM_005264643.1:c.772+6983A>G, XM_005264643.2:c.772+6983A>G, XM_006712137.2:c.772+6983A>G, XM_006712140.2:c.772+6983A>G, XM_006712141.2:c.772+6983A>G, XM_011533167.1:c.772+6983A>G, XM_011533168.1:c.772+6983A>G, XM_011533169.1:c.772+6983A>G, XM_011533170.1:c.772+6983A>G, XM_011533171.1:c.772+6983A>G, XM_011533172.1:c.772+6983A>G, XM_011533173.1:c.772+6983A>G, XM_011533174.1:c.772+6983A>G, XM_011533175.1:c.772+6983A>G, XM_011533176.1:c.772+6983A>G, XM_011533177.1:c.772+6983A>G, XM_011533178.1:c.772+6983A>G, XM_011533179.1:c.772+6983A>G, XM_011533180.1:c.772+6983A>G, rs386513486, rs60675339
T > C
SNP
No VIP available No Clinical Annotations available VA
rs10490624 NC_000002.11:g.118862492T>C, NC_000002.12:g.118104916T>C, NM_016133.2:c.369+1595T>C, XM_005263690.1:c.45+1595T>C, XM_005263690.2:c.45+1595T>C, XM_005263691.1:c.45+1595T>C, XM_011511292.1:c.369+1595T>C, rs17587942, rs386513497
T > C
SNP
No VIP available CA VA
rs10501087 NC_000011.10:g.27648561T>C, NC_000011.9:g.27670108T>C, NR_002832.2:n.374+8556T>C, NR_033312.1:n.305+8556T>C, NR_033313.1:n.305+8556T>C, NR_033314.1:n.374+8556T>C, NR_033315.1:n.305+8556T>C, XR_242807.1:n.223+8556T>C, XR_242808.1:n.223+8556T>C, XR_242809.1:n.223+8556T>C, rs59340138
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1059778 NC_000001.10:g.228372062C>T, NC_000001.11:g.228184361C>T, XM_006711753.2:c.679+9332C>T, rs3200591, rs60458914
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1063539 NC_000003.11:g.186575392G>C, NC_000003.12:g.186857603G>C, NG_021140.1:g.19930G>C, NM_001177800.1:c.*2899G>C, NM_004797.3:c.*2899G>C, NR_046662.1:n.-1480C>G, XM_011513324.1:c.*2899G>C, rs17846874, rs57588137
G > C
SNP
No VIP available No Clinical Annotations available VA
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
No VIP available CA No Variant Annotations available
rs1079598 NC_000011.10:g.113425552A>G, NC_000011.9:g.113296274A>G, NG_008841.1:g.54728T>C, NM_000795.3:c.-31-870T>C, NM_016574.3:c.-31-870T>C, XM_005271425.1:c.-31-870T>C, XM_005271426.1:c.-901T>C, rs4134628, rs4986924, rs61553796
A > G
SNP
No VIP available No Clinical Annotations available VA
rs10807344 NC_000006.11:g.46625635C>T, NC_000006.12:g.46657898C>T, NM_001204051.1:c.299-1064C>T, NM_001204052.1:c.299-1064C>T, NM_004277.4:c.299-1064C>T, XM_005249483.1:c.299-1064C>T, XM_005249483.2:c.299-1064C>T, XM_005249484.1:c.155-1064C>T, XM_005249485.1:c.-17-1064C>T, XR_241952.1:n.547-1064C>T, XR_427858.1:n.547-1064C>T, rs58788242
C > T
SNP
No VIP available No Clinical Annotations available VA
rs10865710 NC_000003.11:g.12353198C>G, NC_000003.12:g.12311699C>G, NG_011749.1:g.28850C>G, NM_005037.5:c.-3+23679C>G, NM_138711.3:c.-76-681C>G, NM_138712.3:c.-76-681C>G, XM_011533840.1:c.-757C>G, XM_011533841.1:c.-3+22565C>G, XM_011533844.1:c.-76-681C>G, rs60017626
C > G
SNP
No VIP available CA VA
rs11030104 NC_000011.10:g.27662970A>G, NC_000011.9:g.27684517A>G, NG_011794.1:g.64089T>C, NM_001143805.1:c.-21-4385T>C, NM_001143806.1:c.-21-4385T>C, NM_001143807.1:c.-21-4385T>C, NM_001143808.1:c.-21-4385T>C, NM_001143809.1:c.67-4385T>C, NM_001143810.1:c.226-4385T>C, NM_001143811.1:c.-138-2698T>C, NM_001143812.1:c.-21-4385T>C, NM_001143813.1:c.-21-4385T>C, NM_001143814.1:c.-128-4044T>C, NM_001709.4:c.-21-4385T>C, NM_170731.4:c.4-4385T>C, NM_170732.4:c.-21-4385T>C, NM_170733.3:c.-21-4385T>C, NM_170734.3:c.25-4385T>C, NR_002832.2:n.654+3742A>G, NR_033312.1:n.585+3742A>G, NR_033313.1:n.585+3742A>G, NR_033314.1:n.654+3742A>G, NR_033315.1:n.585+3742A>G, XM_005253060.1:c.226-4385T>C, XM_011520280.1:c.226-4385T>C, XR_242807.1:n.506+3742A>G, XR_242808.1:n.503+3742A>G, XR_242809.1:n.281+3742A>G, rs57609906
A > G
SNP
No VIP available No Clinical Annotations available VA
rs11123469 NC_000002.11:g.118844183T>C, NC_000002.12:g.118086607T>C, NM_016133.2:c.-2073T>C, XM_005263690.1:c.-2023T>C, XM_005263690.2:c.-2023T>C, XM_005263691.1:c.-2015T>C, XM_011512305.1:c.696+1453A>G, rs56533314
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available CA VA
rs1137101 NC_000001.10:g.66058513A>G, NC_000001.11:g.65592830A>G, NG_015831.2:g.177266A>G, NM_001003679.3:c.668A>G, NM_001003680.3:c.668A>G, NM_001198687.1:c.668A>G, NM_001198688.1:c.668A>G, NM_001198689.1:c.668A>G, NM_002303.5:c.668A>G, NP_001003679.1:p.Gln223Arg, NP_001003680.1:p.Gln223Arg, NP_001185616.1:p.Gln223Arg, NP_001185617.1:p.Gln223Arg, NP_001185618.1:p.Gln223Arg, NP_002294.2:p.Gln223Arg, XM_005270950.1:c.668A>G, XM_005270951.1:c.668A>G, XM_005270952.1:c.668A>G, XP_005271007.1:p.Gln223Arg, XP_005271008.1:p.Gln223Arg, XP_005271009.1:p.Gln223Arg, rs12131454, rs17356624, rs1805093, rs2229418, rs3200842, rs52820808, rs59347832, rs9282885
A > G
SNP
Q223R
No VIP available CA VA
rs1143634 NC_000002.11:g.113590390G>A, NC_000002.12:g.112832813G>A, NG_008851.1:g.8967C>T, NM_000576.2:c.315C>T, NP_000567.1:p.Phe105=, XM_006712496.1:c.81C>T, XP_006712559.1:p.Phe27=, rs11541230, rs17598550, rs3730338, rs386518185, rs57848697
G > A
SNP
F105F
No VIP available No Clinical Annotations available VA
rs1152003 NC_000003.11:g.12477055G>C, NC_000003.12:g.12435556G>C, NG_011749.1:g.152707G>C, XM_011533842.1:c.1270+18402G>C, rs1625302, rs58390878, rs60048336
G > C
SNP
No VIP available No Clinical Annotations available VA
rs1175542 NC_000003.11:g.12466214G>A, NC_000003.12:g.12424715G>A, NG_011749.1:g.141866G>A, NM_005037.5:c.1186+7561G>A, NM_015869.4:c.1270+7561G>A, NM_138711.3:c.1186+7561G>A, NM_138712.3:c.1186+7561G>A, XM_011533840.1:c.1186+7561G>A, XM_011533841.1:c.1186+7561G>A, XM_011533842.1:c.1270+7561G>A, XM_011533843.1:c.820-9183G>A, XM_011533844.1:c.736-9183G>A, rs1699364, rs17241475, rs60112637
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1177809 NC_000003.11:g.12466490A>G, NC_000003.12:g.12424991A>G, NG_011749.1:g.142142A>G, NM_005037.5:c.1186+7837A>G, NM_015869.4:c.1270+7837A>G, NM_138711.3:c.1186+7837A>G, NM_138712.3:c.1186+7837A>G, XM_011533840.1:c.1186+7837A>G, XM_011533841.1:c.1186+7837A>G, XM_011533842.1:c.1270+7837A>G, XM_011533843.1:c.820-8907A>G, XM_011533844.1:c.736-8907A>G, rs17036686, rs17241489, rs1797911
A > G
SNP
No VIP available CA VA
rs12467557 NC_000002.11:g.51242270A>G, NC_000002.12:g.51015132A>G, NG_011878.1:g.22405T>C, NM_001135659.1:c.871+11239T>C, NM_004801.4:c.772+12370T>C, XM_005264642.1:c.772+12370T>C, XM_005264642.2:c.772+12370T>C, XM_005264643.1:c.772+12370T>C, XM_005264643.2:c.772+12370T>C, XM_006712137.2:c.772+12370T>C, XM_006712140.2:c.772+12370T>C, XM_006712141.2:c.772+12370T>C, XM_011533167.1:c.772+12370T>C, XM_011533168.1:c.772+12370T>C, XM_011533169.1:c.772+12370T>C, XM_011533170.1:c.772+12370T>C, XM_011533171.1:c.772+12370T>C, XM_011533172.1:c.772+12370T>C, XM_011533173.1:c.772+12370T>C, XM_011533174.1:c.772+12370T>C, XM_011533175.1:c.772+12370T>C, XM_011533176.1:c.772+12370T>C, XM_011533177.1:c.772+12370T>C, XM_011533178.1:c.772+12370T>C, XM_011533179.1:c.772+12370T>C, XM_011533180.1:c.772+12370T>C
A > G
SNP
No VIP available No Clinical Annotations available VA
rs12495941 NC_000003.11:g.186568180G>T, NC_000003.12:g.186850391G>T, NG_021140.1:g.12718G>T, NM_001177800.1:c.-8-2660G>T, NM_004797.3:c.-8-2660G>T, XM_011513324.1:c.-124-715G>T, rs59339333
G > T
SNP
No VIP available No Clinical Annotations available VA
rs12629751 NC_000003.11:g.12399407C>T, NC_000003.12:g.12357908C>T, NG_011749.1:g.75059C>T, NM_005037.5:c.-2-21796C>T, NM_015869.4:c.82+6234C>T, NM_138711.3:c.-2-21796C>T, NM_138712.3:c.-2-21796C>T, XM_011533840.1:c.-2-21796C>T, XM_011533841.1:c.-2-21796C>T, XM_011533842.1:c.82+6234C>T, XM_011533843.1:c.82+6234C>T, XM_011533844.1:c.-2-21796C>T, rs60837059
C > T
SNP
No VIP available CA VA
rs13250975 NC_000008.10:g.32392809A>G, NC_000008.11:g.32535292A>G, NG_012005.1:g.900542A>G, NM_001159995.1:c.38-60537A>G, NM_001159999.1:c.38-60537A>G, NM_001160001.1:c.38-60537A>G, NM_013962.2:c.746-60537A>G, XM_005273488.1:c.122-60537A>G, XM_011544512.1:c.122-60536A>G, rs57207719
A > G
SNP
No VIP available CA VA
rs1344706 NC_000002.11:g.185778428A>C, NC_000002.12:g.184913701A>C, NM_194250.1:c.256-19902A>C, rs386528769, rs59623514
A > C
SNP
No VIP available No Clinical Annotations available VA
rs1379357 NC_000008.10:g.24781579G>C, NC_000008.11:g.24924066G>C, XR_949590.1:n.42+524C>G
G > C
SNP
No VIP available CA VA
rs1414334 NC_000023.10:g.114138144C>G, NC_000023.11:g.114903581C>G, NG_012082.2:g.324497C>G, NM_000868.3:c.551-3008C>G, NM_001256760.2:c.551-3008C>G, NM_001256761.2:c.456-3008C>G, NW_004070891.1:g.572383C>G, rs59611151
C > G
SNP
No VIP available No Clinical Annotations available VA
rs1421085 NC_000016.10:g.53767042T>C, NC_000016.9:g.53800954T>C, NG_012969.1:g.68080T>C, NM_001080432.2:c.46-43098T>C, XM_011523313.1:c.46-43098T>C, XM_011523314.1:c.46-43098T>C, XM_011523315.1:c.46-43098T>C, XM_011523316.1:c.46-43098T>C, rs17817021
T > C
SNP
No VIP available No Clinical Annotations available VA
rs14240 NC_000010.10:g.119037071T>C, NC_000010.11:g.117277560T>C, NM_003054.4:c.*294T>C, XR_246069.1:n.1581-7117A>G, rs3168025, rs363234, rs3758625, rs386491448, rs60529903
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1457266 NC_000008.10:g.24769852A>G, NC_000008.11:g.24912339A>G, NG_008388.1:g.3579A>G, NM_005382.2:c.-1455A>G, XM_005273507.1:c.-1455A>G, XM_005273508.1:c.-1455A>G, XR_949590.1:n.194+8445T>C, rs3824126
A > G
A > T
SNP
No VIP available CA VA
rs1468412 NC_000007.13:g.86433451A>T, NC_000007.14:g.86804135A>T, NM_000840.2:c.1324+17019A>T, XM_005250286.1:c.1324+17019A>T, XM_005250287.1:c.940+17019A>T, XM_005250288.1:c.1324+17019A>T, XM_005250289.1:c.101-34704A>T, XM_005250290.1:c.1324+17019A>T, XM_011516088.1:c.1324+17019A>T, XM_011516089.1:c.1325-10952A>T, XM_011516090.1:c.1324+17019A>T, rs10331026, rs10480415, rs17161010
A > T
SNP
No VIP available No Clinical Annotations available VA
rs1529461 NC_000005.10:g.36689261A>G, NC_000005.9:g.36689363A>G, NG_015890.1:g.87907A>G, rs57230569
A > G
SNP
No VIP available CA VA
rs1544938 NC_000005.10:g.7634119G>C, NC_000005.9:g.7634232G>C, NM_020546.2:c.720+7803G>C, XM_011513942.1:c.720+7803G>C, XR_427657.2:n.734+7803G>C, rs61224038
G > C
SNP
No VIP available No Clinical Annotations available VA
rs1656930 NC_000003.11:g.186552857A>G, NC_000003.12:g.186835068A>G, rs4505690, rs59137900, rs6444168
A > G
SNP
No VIP available No Clinical Annotations available VA
rs165815
C > T
SNP
R906Q
No VIP available No Clinical Annotations available VA
rs165854 NC_000022.10:g.21167787G>A, NC_000022.11:g.20813499G>A, NG_033052.1:g.50314C>T, NM_058004.3:c.864C>T, NP_477352.3:p.Cys288=, XM_005261634.1:c.948C>T, XM_005261635.1:c.948C>T, XM_005261636.1:c.948C>T, XM_011530226.1:c.948C>T, XM_011530227.1:c.948C>T, XM_011530228.1:c.948C>T, XP_005261691.1:p.Cys316=, XP_005261692.1:p.Cys316=, XP_005261693.1:p.Cys316=, XP_011528528.1:p.Cys316=, XP_011528529.1:p.Cys316=, XP_011528530.1:p.Cys316=, XR_937868.1:n.951C>T, rs1210480, rs17820235, rs534162, rs59270229
G > A
SNP
C288C
No VIP available No Clinical Annotations available VA
rs16860087 NC_000004.11:g.47229247C>A, NC_000004.12:g.47227230C>A, NM_000812.3:c.461+65761C>A, XM_005248081.1:c.461+65761C>A, XM_011513678.1:c.440+65761C>A
C > A
SNP
No VIP available No Clinical Annotations available VA
rs16861210 NC_000003.11:g.186566498G>A, NC_000003.12:g.186848709G>A, NG_021140.1:g.11036G>A, NM_001177800.1:c.-9+3102G>A, NM_004797.3:c.-8-4342G>A, XM_011513324.1:c.-124-2397G>A
G > A
SNP
No VIP available CA VA
rs16944 NC_000002.11:g.113594867A>G, NC_000002.12:g.112837290A>G, NG_008851.1:g.4490T>C, NM_000576.2:c.-598T>C, XM_006712496.1:c.-1552T>C, rs3827762
A > G
SNP
No VIP available No Clinical Annotations available VA
rs17036160 NC_000003.11:g.12329783C>T, NC_000003.12:g.12288284C>T, NG_011749.1:g.5435C>T, NM_005037.5:c.-3+264C>T, NM_138711.3:c.-927C>T, NM_138712.3:c.-77+264C>T, XM_011533841.1:c.-853C>T, XM_011533844.1:c.-927C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs17047764 NC_000002.11:g.118868582G>C, NC_000002.12:g.118111006G>C
G > C
SNP
No VIP available CA VA
rs17587100 NC_000002.11:g.118838410A>C, NC_000002.12:g.118080834A>C, XM_011512305.1:c.697-3302T>G
A > C
SNP
No VIP available CA VA
rs17716295 NC_000008.10:g.32317917C>A, NC_000008.11:g.32460401C>A, NG_012005.1:g.825650C>A, NM_001159995.1:c.38-135429C>A, NM_001159999.1:c.38-135429C>A, NM_001160001.1:c.38-135429C>A, NM_013962.2:c.746-135429C>A, XM_005273488.1:c.122-135429C>A, XM_011544512.1:c.122-135427C>A, rs58517519
C > A
SNP
No VIP available CA VA
rs17782313 NC_000018.10:g.60183864T>C, NC_000018.9:g.57851097T>C, rs59090733, rs59781239
T > C
SNP
No VIP available No Clinical Annotations available VA
rs17793693 NC_000003.11:g.12345971C>A, NC_000003.12:g.12304472C>A, NG_011749.1:g.21623C>A, NM_005037.5:c.-3+16452C>A, NM_138711.3:c.-76-7908C>A, NM_138712.3:c.-76-7908C>A, XM_011533841.1:c.-3+15338C>A, XM_011533844.1:c.-76-7908C>A, rs59306468
C > A
SNP
No VIP available No Clinical Annotations available VA
rs1797912 NC_000003.11:g.12470239A>C, NC_000003.12:g.12428740A>C, NG_011749.1:g.145891A>C, NM_005037.5:c.1187-5158A>C, NM_015869.4:c.1271-5158A>C, NM_138711.3:c.1187-5158A>C, NM_138712.3:c.1187-5158A>C, XM_011533840.1:c.1187-5158A>C, XM_011533841.1:c.1187-5158A>C, XM_011533842.1:c.1270+11586A>C, XM_011533843.1:c.820-5158A>C, XM_011533844.1:c.736-5158A>C, rs17247893, rs3773361, rs59257271
A > C
SNP
No VIP available CA VA
rs1799732 NC_000011.10:g.113475529_113475530insG, NC_000011.9:g.113346251_113346252insG, NG_008841.1:g.4750_4751insC, NM_000795.3:c.-486_-485insC, NM_016574.3:c.-486_-485insC, XM_005271425.1:c.-32+128_-32+129insC, XR_948023.1:n.528_529insC, rs143987432, rs144707848, rs72523179, rs72566141
- > G
indel
VIP No Clinical Annotations available No Variant Annotations available
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available No Clinical Annotations available VA
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available CA VA
rs1800497 NC_000011.10:g.113400106G>A, NC_000011.9:g.113270828G>A, NG_012976.1:g.17316G>A, NM_178510.1:c.2137G>A, NP_848605.1:p.Glu713Lys, XM_011542736.1:c.2170G>A, XM_011542737.1:c.2140G>A, XM_011542738.1:c.1948G>A, XP_011541038.1:p.Glu724Lys, XP_011541039.1:p.Glu714Lys, XP_011541040.1:p.Glu650Lys, rs117686243, rs4134623, rs4245144, rs59538675
G > A
SNP
E713K
No VIP available No Clinical Annotations available VA
rs1801028 NC_000011.10:g.113412762G>C, NC_000011.9:g.113283484G>C, NG_008841.1:g.67518C>G, NM_000795.3:c.932C>G, NM_016574.3:c.845C>G, NP_000786.1:p.Ser311Cys, NP_057658.2:p.Ser282Cys, XM_005271425.1:c.932C>G, XM_005271426.1:c.929C>G, XP_005271482.1:p.Ser311Cys, XP_005271483.1:p.Ser310Cys, rs4134622
G > C
SNP
S311C
No VIP available CA VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available No Clinical Annotations available VA
rs1801282 NC_000003.11:g.12393125C>G, NC_000003.12:g.12351626C>G, NG_011749.1:g.68777C>G, NM_005037.5:c.-2-28078C>G, NM_015869.4:c.34C>G, NM_138711.3:c.-2-28078C>G, NM_138712.3:c.-2-28078C>G, NP_056953.2:p.Pro12Ala, XM_011533840.1:c.-2-28078C>G, XM_011533841.1:c.-2-28078C>G, XM_011533842.1:c.34C>G, XM_011533843.1:c.34C>G, XM_011533844.1:c.-2-28078C>G, XP_011532144.1:p.Pro12Ala, XP_011532145.1:p.Pro12Ala, rs17241090, rs17749580, rs36206375, rs56460253, rs57327233
C > G
SNP
P12A
No VIP available CA VA
rs1805128 NC_000021.8:g.35821680C>T, NC_000021.9:g.34449382C>T, NG_009091.1:g.66934G>A, NM_000219.3:c.253G>A, NM_000219.5:c.253G>A, NM_001127668.3:c.253G>A, NM_001127669.3:c.253G>A, NM_001127670.1:c.253G>A, NM_001127670.3:c.253G>A, NM_001270402.2:c.253G>A, NM_001270403.2:c.253G>A, NM_001270404.2:c.253G>A, NM_001270405.2:c.253G>A, NP_000210.2:p.Asp85Asn, NP_001121140.1:p.Asp85Asn, NP_001121141.1:p.Asp85Asn, NP_001121142.1:p.Asp85Asn, NP_001257331.1:p.Asp85Asn, NP_001257332.1:p.Asp85Asn, NP_001257333.1:p.Asp85Asn, NP_001257334.1:p.Asp85Asn, XM_005260972.1:c.316G>A, XM_005260973.1:c.13+6004G>A, XM_011529555.1:c.13+6004G>A, XM_011529557.1:c.279+9272G>A, XP_005261029.1:p.Asp106Asn, rs17173507, rs52820407
C > T
SNP
D85N
No VIP available No Clinical Annotations available VA
rs182052 NC_000003.11:g.186560782G>A, NC_000003.12:g.186842993G>A, NG_021140.1:g.5320G>A, NM_001177800.1:c.-60+244G>A, NM_004797.3:c.-9+244G>A, XM_011513324.1:c.-125+244G>A, rs1656945, rs56428779, rs57471283
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1990761 NC_000002.11:g.162997703G>A, NC_000002.12:g.162141193G>A, NR_110255.1:n.93-20577G>A, XR_241339.1:n.93-20577G>A, rs17710539, rs59802638
G > A
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2036373 NC_000003.11:g.186570191T>G, NC_000003.12:g.186852402T>G, NG_021140.1:g.14729T>G, NM_001177800.1:c.-8-649T>G, NM_004797.3:c.-8-649T>G, NR_046662.1:n.2927A>C, XM_011513324.1:c.-8-649T>G, rs36219759, rs58651489
T > A
T > C
SNP
No VIP available CA VA
rs2061051 NC_000015.10:g.27275664G>A, NC_000015.9:g.27520811G>A, NG_032887.1:g.309383G>A, NM_001270873.1:c.271-51145G>A, NM_033223.4:c.271-51145G>A, XM_011521430.1:c.271-51145G>A, XR_932013.1:n.111+4027G>A, rs17672404
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2067482 NC_000011.10:g.46385217G>A, NC_000011.9:g.46406767G>A, NM_000741.3:c.1341C>T, NP_000732.2:p.Thr447=, XM_005252770.1:c.1341C>T, XP_005252827.1:p.Thr447=
G > A
SNP
T447T
No VIP available CA VA
rs2069514 NC_000015.10:g.74745879G>A, NC_000015.9:g.75038220G>A, NG_008431.1:g.28338G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2070744 NC_000007.13:g.150690079C=, NC_000007.13:g.150690079C>T, NC_000007.14:g.150992991C=, NC_000007.14:g.150992991C>T, NG_011992.1:g.6933C=, NG_011992.1:g.6933C>T, NM_000603.4:c.-51-762C=, NM_000603.4:c.-51-762C>T, NM_001160109.1:c.-813C=, NM_001160109.1:c.-813C>T, NM_001160110.1:c.-813C=, NM_001160110.1:c.-813C>T, NM_001160111.1:c.-813C=, NM_001160111.1:c.-813C>T, XM_006716002.2:c.-813C=, XM_006716002.2:c.-813C>T, rs10333298, rs34629525, rs61324345
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2120825 NC_000003.11:g.12413339T>G, NC_000003.12:g.12371840T>G, NG_011749.1:g.88991T>G, NM_005037.5:c.-2-7864T>G, NM_015869.4:c.83-7864T>G, NM_138711.3:c.-2-7864T>G, NM_138712.3:c.-2-7864T>G, XM_011533840.1:c.-2-7864T>G, XM_011533841.1:c.-2-7864T>G, XM_011533842.1:c.83-7864T>G, XM_011533843.1:c.83-7864T>G, XM_011533844.1:c.-2-7864T>G, rs59885468
T > G
SNP
No VIP available No Clinical Annotations available VA
rs2235800 NC_000023.10:g.129498836T>A, NC_000023.11:g.130364862T>A, NG_012850.1:g.29790T>A, NM_001282195.1:c.719+110T>A, NM_001282196.1:c.710+110T>A, NM_001282197.1:c.803+110T>A, NM_001282198.1:c.614+110T>A, NM_003951.2:c.719+110T>A, NM_022810.1:c.710+110T>A, NR_104107.1:n.647+110T>A, XM_005262485.1:c.803+110T>A, XM_005262486.1:c.719+110T>A, XM_005262487.1:c.710+110T>A, XM_005262488.1:c.614+110T>A, XM_005262489.1:c.416+110T>A, XM_005262489.3:c.416+110T>A, XM_011531402.1:c.746+110T>A, XR_244526.1:n.787+110T>A, XR_244527.1:n.897T>A, rs17305320, rs56506222
T > A
SNP
No VIP available No Clinical Annotations available VA
rs2239483 NC_000023.10:g.129477451A>G, NC_000023.11:g.130343477A>G, NG_012850.1:g.8405A>G, NM_001282195.1:c.76-1705A>G, NM_001282196.1:c.67-1705A>G, NM_001282197.1:c.67-1705A>G, NM_001282198.1:c.-30-1705A>G, NM_003951.2:c.76-1705A>G, NM_022810.1:c.67-1705A>G, NR_104107.1:n.90-1705A>G, XM_005262485.1:c.160-1705A>G, XM_005262486.1:c.76-1705A>G, XM_005262487.1:c.67-1705A>G, XM_005262488.1:c.-30-1705A>G, XM_005262489.1:c.14+3501A>G, XM_005262489.3:c.14+3501A>G, XM_011531402.1:c.103-1705A>G, XM_011531403.1:c.-30-1705A>G, XM_011531404.1:c.67-1705A>G, XM_011531405.1:c.-30-1705A>G, XR_244526.1:n.230-1705A>G, XR_244527.1:n.230-1705A>G
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2241766 NC_000003.11:g.186570892T>G, NC_000003.12:g.186853103T>G, NG_021140.1:g.15430T>G, NM_001177800.1:c.45T>G, NM_004797.3:c.45T>G, NP_001171271.1:p.Gly15=, NP_004788.1:p.Gly15=, NR_046662.1:n.2226A>C, XM_011513324.1:c.45T>G, XP_011511626.1:p.Gly15=, rs17846867, rs36219441
T > -
T > C
SNP
G15G
No VIP available No Clinical Annotations available VA
rs2270450 NC_000006.11:g.46644875C>T, NC_000006.12:g.46677138C>T, NM_001204051.1:c.*489C>T, NM_001204052.1:c.*458C>T, NM_004277.4:c.*684C>T, NR_134642.1:n.235-6553G>A, NR_134643.1:n.233-6553G>A, NR_134644.1:n.160-6553G>A, XM_005249483.1:c.*556C>T, XM_005249483.2:c.*556C>T, XM_005249484.1:c.*684C>T, XM_005249485.1:c.*684C>T, XR_241952.1:n.1049+395C>T, XR_242029.1:n.252-6553G>A, XR_242029.2:n.235-6553G>A, XR_242030.1:n.82-6553G>A, XR_427858.1:n.1509+395C>T, rs17288886, rs59086356
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2299214 NC_000007.13:g.86309106C>T, NC_000007.14:g.86679790C>T, NM_000840.2:c.-141+34918C>T, XM_005250287.1:c.84+34918C>T, XM_005250289.1:c.100+34918C>T, XM_011516088.1:c.-141+34918C>T, XM_011516089.1:c.-141+34918C>T, XM_011516090.1:c.-141+34918C>T, rs60400850, rs9791754
C > T
SNP
No VIP available CA VA
rs2445142 NC_000001.10:g.22225743G>C, NC_000001.11:g.21899250G>C, NG_016740.1:g.43008C>G, NM_001291860.1:c.64-2940C>G, NM_005529.6:c.64-2940C>G, XM_005245859.1:c.64-2940C>G, XM_005245860.1:c.64-2940C>G, XM_005245861.1:c.64-2940C>G, XM_005245862.1:c.64-2940C>G, XM_005245863.1:c.64-2940C>G, XM_005245865.1:c.64-2940C>G, XM_006710594.2:c.64-2940C>G, XM_006710595.2:c.64-2940C>G, XM_006710596.2:c.64-2940C>G, XM_006710597.2:c.64-2940C>G, XM_011541317.1:c.64-2940C>G, XM_011541318.1:c.64-2940C>G, XM_011541319.1:c.64-2940C>G, XM_011541320.1:c.64-2940C>G, XM_011541321.1:c.64-2940C>G, XM_011541322.1:c.64-2940C>G, rs17426667, rs56637658, rs59538631
G > C
SNP
No VIP available No Clinical Annotations available VA
rs2485914 NC_000001.10:g.246220746T>C, NC_000001.11:g.246057444T>C, NM_001167740.1:c.532-127507A>G, NM_022743.2:c.355-127507A>G, XM_005273227.1:c.532-127507A>G, XM_005273228.1:c.532-127507A>G, XM_005273230.1:c.-36-127507A>G, XM_011544253.1:c.532-127507A>G, XM_011544254.1:c.105+50636A>G, XM_011544255.1:c.60+126972A>G, XM_011544256.1:c.25-127507A>G, XM_011544258.1:c.-36-127507A>G, XM_011544261.1:c.-37+119021A>G, XR_949153.1:n.633-127507A>G, rs56445665, rs57061101
T > C
SNP
No VIP available CA VA
rs2513265 NC_000011.10:g.105553068T>A, NC_000011.9:g.105423795T>A, rs17469263, rs59115101, rs60930732
T > A
SNP
No VIP available No Clinical Annotations available VA
rs25531 NC_000017.10:g.28564346T>C, NC_000017.11:g.30237328T>C, NG_011747.2:g.3609A>G, NM_001045.5:c.-1936A>G, XM_005258025.1:c.-1810A>G, XR_934652.1:n.-225T>C, XR_934653.1:n.-225T>C, XR_934654.1:n.165+258T>C, XR_934655.1:n.-225T>C, rs2020931, rs35593448
T > C
SNP
No VIP available No Clinical Annotations available VA
rs266729 NC_000003.11:g.186559474C>G, NC_000003.12:g.186841685C>G, NG_021140.1:g.4012C>G, NM_001177800.1:c.-1124C>G, NM_004797.3:c.-1073C>G, XM_011513324.1:c.-1189C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2920500 NC_000003.11:g.12323413G>A, NC_000003.12:g.12281914G>A, rs57684379
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2960421 NC_000003.11:g.12322628A>G, NC_000003.12:g.12281129A>G
A > G
SNP
No VIP available No Clinical Annotations available VA
rs35859249 NC_000004.11:g.37904089C>T, NC_000004.12:g.37902468C>T, NM_001253912.1:c.373C>T, NM_015173.3:c.373C>T, NP_001240841.1:p.Arg125Trp, NP_055988.2:p.Arg125Trp, XM_005262646.1:c.373C>T, XM_005262647.1:c.373C>T, XM_005262648.1:c.373C>T, XM_005262650.1:c.373C>T, XM_011513659.1:c.373C>T, XM_011513660.1:c.373C>T, XM_011513661.1:c.373C>T, XM_011513662.1:c.373C>T, XM_011513663.1:c.373C>T, XM_011513664.1:c.373C>T, XM_011513665.1:c.373C>T, XM_011513666.1:c.373C>T, XM_011513667.1:c.373C>T, XM_011513668.1:c.373C>T, XP_005262703.1:p.Arg125Trp, XP_005262704.1:p.Arg125Trp, XP_005262705.1:p.Arg125Trp, XP_005262707.1:p.Arg125Trp, XP_011511961.1:p.Arg125Trp, XP_011511962.1:p.Arg125Trp, XP_011511963.1:p.Arg125Trp, XP_011511964.1:p.Arg125Trp, XP_011511965.1:p.Arg125Trp, XP_011511966.1:p.Arg125Trp, XP_011511967.1:p.Arg125Trp, XP_011511968.1:p.Arg125Trp, XP_011511969.1:p.Arg125Trp, XP_011511970.1:p.Arg125Trp, rs61752237
C > T
SNP
R125W
No VIP available No Clinical Annotations available VA
rs363224 NC_000010.10:g.119022573C>A, NC_000010.11:g.117263062C>A, NM_003054.4:c.992-3671C>A, rs17543598, rs56467431, rs57914512
C > A
SNP
No VIP available No Clinical Annotations available VA
rs363390 NC_000010.10:g.119004079G>C, NC_000010.11:g.117244568G>C, NM_003054.4:c.464+255G>C, XR_946342.1:n.-1805C>G, rs59729204
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3757241 NC_000006.11:g.46623698T>C, NC_000006.12:g.46655961T>C, NG_007962.1:g.1826A>G, NM_001204051.1:c.225T>C, NM_001204052.1:c.225T>C, NM_004277.4:c.225T>C, NP_001190980.1:p.Ala75=, NP_001190981.1:p.Ala75=, NP_004268.3:p.Ala75=, XM_005249483.1:c.225T>C, XM_005249483.2:c.225T>C, XM_005249484.1:c.81T>C, XM_005249485.1:c.-87T>C, XP_005249540.1:p.Ala75=, XP_005249541.1:p.Ala27=, XR_241952.1:n.473T>C, XR_427858.1:n.473T>C, rs17216715, rs17846034, rs17859019, rs61168124
T > C
SNP
A75A
No VIP available No Clinical Annotations available VA
rs3761656 NC_000002.11:g.163011235T>G, NC_000002.12:g.162154725T>G, NR_110255.1:n.93-7045T>G, XR_241339.1:n.93-7045T>G, rs117845058, rs60722133
T > G
SNP
No VIP available No Clinical Annotations available VA
rs3774261 NC_000003.11:g.186571559A>G, NC_000003.12:g.186853770A>G, NG_021140.1:g.16097A>G, NM_001177800.1:c.215-414A>G, NM_004797.3:c.215-414A>G, NR_046662.1:n.2086+8T>C, XM_011513324.1:c.215-414A>G, rs28973164, rs59618226, rs60811615
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3813928 NC_000023.10:g.113818282G>A, NC_000023.11:g.114583809G>A, NG_012082.2:g.4725G>A, NM_000868.3:c.-997G>A, NM_001256760.2:c.-1088G>A, NM_001256761.2:c.-997G>A, NW_004070891.1:g.252611G>A, rs17260544, rs56468477, rs58438880
G > A
SNP
No VIP available CA VA
rs3813929 NC_000023.10:g.113818520C>T, NC_000023.11:g.114584047C>T, NG_012082.2:g.4963C>T, NM_000868.3:c.-759C>T, NM_001256760.2:c.-850C>T, NM_001256761.2:c.-759C>T, NW_004070891.1:g.252849C>T, rs17326402
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3821799 NC_000003.11:g.186571486T>C, NC_000003.12:g.186853697T>C, NG_021140.1:g.16024T>C, NM_001177800.1:c.214+425T>C, NM_004797.3:c.214+425T>C, NR_046662.1:n.2086+81A>G, XM_011513324.1:c.214+425T>C, rs17300854, rs56544256, rs57312489
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3856806 NC_000003.11:g.12475557C>T, NC_000003.12:g.12434058C>T, NG_011749.1:g.151209C>T, NM_005037.5:c.1347C>T, NM_015869.4:c.1431C>T, NM_138711.3:c.1347C>T, NM_138712.3:c.1347C>T, NP_005028.4:p.His449=, NP_056953.2:p.His477=, NP_619725.2:p.His449=, NP_619726.2:p.His449=, XM_011533840.1:c.1347C>T, XM_011533841.1:c.1347C>T, XM_011533842.1:c.1270+16904C>T, XM_011533843.1:c.*143C>T, XM_011533844.1:c.*143C>T, XP_011532142.1:p.His449=, XP_011532143.1:p.His449=, rs17241555, rs56980657
C > T
SNP
H449H
No VIP available No Clinical Annotations available VA
rs4135247 NC_000003.11:g.12396588G>A, NC_000003.12:g.12355089G>A, NG_011749.1:g.72240G>A, NM_005037.5:c.-2-24615G>A, NM_015869.4:c.82+3415G>A, NM_138711.3:c.-2-24615G>A, NM_138712.3:c.-2-24615G>A, XM_011533840.1:c.-2-24615G>A, XM_011533841.1:c.-2-24615G>A, XM_011533842.1:c.82+3415G>A, XM_011533843.1:c.82+3415G>A, XM_011533844.1:c.-2-24615G>A, rs17247494, rs17817246
G > A
SNP
No VIP available No Clinical Annotations available VA
rs4135256 NC_000003.11:g.12409528A>G, NC_000003.12:g.12368029A>G, NG_011749.1:g.85180A>G, NM_005037.5:c.-2-11675A>G, NM_015869.4:c.83-11675A>G, NM_138711.3:c.-2-11675A>G, NM_138712.3:c.-2-11675A>G, XM_011533840.1:c.-2-11675A>G, XM_011533841.1:c.-2-11675A>G, XM_011533842.1:c.83-11675A>G, XM_011533843.1:c.83-11675A>G, XM_011533844.1:c.-2-11675A>G, rs17241583
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4135258 NC_000003.11:g.12418596C>T, NC_000003.12:g.12377097C>T, NG_011749.1:g.94248C>T, NM_005037.5:c.-2-2607C>T, NM_015869.4:c.83-2607C>T, NM_138711.3:c.-2-2607C>T, NM_138712.3:c.-2-2607C>T, XM_011533840.1:c.-2-2607C>T, XM_011533841.1:c.-2-2607C>T, XM_011533842.1:c.83-2607C>T, XM_011533843.1:c.83-2607C>T, XM_011533844.1:c.-2-2607C>T, rs17247571
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4135268 NC_000003.11:g.12437237C>G, NC_000003.12:g.12395738C>G, NG_011749.1:g.112889C>G, NM_005037.5:c.535+2986C>G, NM_015869.4:c.619+2986C>G, NM_138711.3:c.535+2986C>G, NM_138712.3:c.535+2986C>G, XM_011533840.1:c.535+2986C>G, XM_011533841.1:c.535+2986C>G, XM_011533842.1:c.619+2986C>G, XM_011533843.1:c.619+2986C>G, XM_011533844.1:c.535+2986C>G, rs17247655, rs17818032, rs56630764
C > G
SNP
No VIP available No Clinical Annotations available VA
rs4135275 NC_000003.11:g.12443844A>G, NC_000003.12:g.12402345A>G, NG_011749.1:g.119496A>G, NM_005037.5:c.536-3537A>G, NM_015869.4:c.620-3537A>G, NM_138711.3:c.536-3537A>G, NM_138712.3:c.536-3537A>G, XM_011533840.1:c.536-3537A>G, XM_011533841.1:c.536-3537A>G, XM_011533842.1:c.620-3537A>G, XM_011533843.1:c.620-3537A>G, XM_011533844.1:c.536-3537A>G, rs17247718, rs60750931
A > G
SNP
No VIP available No Clinical Annotations available VA
rs41368446 NC_000002.11:g.162998113T>G, NC_000002.12:g.162141603T>G, NR_110255.1:n.93-20167T>G, XR_241339.1:n.93-20167T>G, rs56630190
T > G
SNP
No VIP available No Clinical Annotations available VA
rs4532 NC_000005.10:g.175443147C>T, NC_000005.9:g.174870150C>T, NG_011802.1:g.6014G>A, NM_000794.3:c.-48G>A, rs1310294, rs265980, rs61505681
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4586 NC_000017.10:g.32583269T>C, NC_000017.11:g.34256250T>C, NG_012123.1:g.5974T>C, NM_002982.3:c.105T>C, NP_002973.1:p.Cys35=, rs2071446, rs2228016, rs3091333, rs3169684, rs57567549
T > C
SNP
C35C
No VIP available CA VA
rs4606 NC_000001.10:g.192781172C>G, NC_000001.11:g.192812042C>G, NG_012800.1:g.8004C>G, NM_002923.3:c.*446C>G, rs16865112, rs3171061, rs60068188
C > G
SNP
No VIP available No Clinical Annotations available VA
rs4627835 NC_000004.11:g.47310267A>T, NC_000004.12:g.47308250A>T, NM_000812.3:c.462-11877A>T, XM_005248081.1:c.462-11877A>T, XM_011513678.1:c.441-11877A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs4633 NC_000022.10:g.19950235C>T, NC_000022.11:g.19962712C>T, NG_011526.1:g.25973C>T, NM_000754.3:c.186C>T, NM_001135161.1:c.186C>T, NM_001135162.1:c.186C>T, NM_007310.2:c.36C>T, NP_000745.1:p.His62=, NP_001128633.1:p.His62=, NP_001128634.1:p.His62=, NP_009294.1:p.His12=, NR_039918.1:n.-1041C>T, XM_005261229.1:c.186C>T, XM_011529885.1:c.300C>T, XM_011529886.1:c.300C>T, XM_011529887.1:c.186C>T, XM_011529888.1:c.186C>T, XM_011529889.1:c.186C>T, XM_011529890.1:c.186C>T, XM_011529891.1:c.186C>T, XP_005261286.1:p.His62=, XP_011528187.1:p.His100=, XP_011528188.1:p.His100=, XP_011528189.1:p.His62=, XP_011528190.1:p.His62=, XP_011528191.1:p.His62=, XP_011528192.1:p.His62=, XP_011528193.1:p.His62=, rs165735, rs17349382, rs17818166, rs2070105, rs3171582, rs4906, rs58430367, rs752985
C > T
SNP
H62H
rs4680 NC_000022.10:g.19951271G>A, NC_000022.11:g.19963748G>A, NG_011526.1:g.27009G>A, NM_000754.3:c.472G>A, NM_001135161.1:c.472G>A, NM_001135162.1:c.472G>A, NM_007310.2:c.322G>A, NP_000745.1:p.Val158Met, NP_001128633.1:p.Val158Met, NP_001128634.1:p.Val158Met, NP_009294.1:p.Val108Met, NR_039918.1:n.-5G>A, XM_005261229.1:c.472G>A, XM_011529885.1:c.586G>A, XM_011529886.1:c.586G>A, XM_011529887.1:c.472G>A, XM_011529888.1:c.472G>A, XM_011529889.1:c.472G>A, XM_011529890.1:c.472G>A, XM_011529891.1:c.472G>A, XP_005261286.1:p.Val158Met, XP_011528187.1:p.Val196Met, XP_011528188.1:p.Val196Met, XP_011528189.1:p.Val158Met, XP_011528190.1:p.Val158Met, XP_011528191.1:p.Val158Met, XP_011528192.1:p.Val158Met, XP_011528193.1:p.Val158Met, rs1131157, rs11544671, rs165688, rs17295216, rs17349704, rs17818178, rs17849308, rs17850006, rs2070104, rs3177905, rs3190784, rs3747070, rs58002978
G > A
SNP
V158M
No VIP available No Clinical Annotations available VA
rs4795893 NC_000017.10:g.32574448G>A, NC_000017.11:g.34247429G>A, rs59800174
G > A
SNP
No VIP available CA VA
rs4849127 NC_000002.11:g.113602559A>G, NC_000002.12:g.112844982A>G, rs60697613
A > G
SNP
No VIP available CA VA
rs5030655 NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709
A > -
A > A
indel
W152G
No VIP available No Clinical Annotations available VA
rs518147 NC_000023.10:g.113818582G=, NC_000023.10:g.113818582G>C, NC_000023.11:g.114584109C>G, NG_012082.2:g.5025C=, NG_012082.2:g.5025C>G, NM_000868.3:c.-697C=, NM_000868.3:c.-697C>G, NM_001256760.2:c.-788C=, NM_001256760.2:c.-788C>G, NM_001256761.2:c.-697C=, NM_001256761.2:c.-697C>G, NW_004070891.1:g.252911C=, NW_004070891.1:g.252911C>G, rs17326409, rs3813930
G > C
SNP
No VIP available No Clinical Annotations available VA
rs5326 NC_000005.10:g.175443193C>T, NC_000005.9:g.174870196C>T, NG_011802.1:g.5968G>A, NM_000794.3:c.-94G>A, rs59257322
C > T
SNP
No VIP available No Clinical Annotations available VA
rs586773 NC_000011.10:g.73985565A>T, NC_000011.9:g.73696610A>T, NG_011478.1:g.2280T>A, rs59870849
A > T
SNP
No VIP available No Clinical Annotations available VA
rs591758 NC_000011.10:g.73987015G>C, NC_000011.9:g.73698060G>C, NG_011478.1:g.830C>G, rs58859716
G > A
G > C
SNP
No VIP available No Clinical Annotations available VA
rs5977250 NC_000023.10:g.129506392T>C, NC_000023.11:g.130372418T>C, NG_012850.1:g.37346T>C, NM_001282195.1:c.937-491T>C, NM_001282196.1:c.928-491T>C, NM_001282197.1:c.1021-491T>C, NM_001282198.1:c.832-491T>C, NM_003951.2:c.937-491T>C, NM_022810.1:c.928-491T>C, NR_104107.1:n.865-491T>C, XM_005262485.1:c.1021-491T>C, XM_005262486.1:c.937-491T>C, XM_005262487.1:c.928-491T>C, XM_005262488.1:c.832-491T>C, XM_005262489.1:c.634-491T>C, XM_005262489.3:c.634-491T>C, XM_011531402.1:c.964-491T>C, XR_244526.1:n.1005-491T>C, XR_244527.1:n.1793-491T>C, rs60526084, rs7058122
T > C
SNP
No VIP available CA VA
rs6265 NC_000011.10:g.27658369C>T, NC_000011.9:g.27679916C>T, NG_011794.1:g.68690G>A, NM_001143805.1:c.196G>A, NM_001143806.1:c.196G>A, NM_001143807.1:c.196G>A, NM_001143808.1:c.196G>A, NM_001143809.1:c.283G>A, NM_001143810.1:c.442G>A, NM_001143811.1:c.196G>A, NM_001143812.1:c.196G>A, NM_001143813.1:c.196G>A, NM_001143814.1:c.196G>A, NM_001143816.1:c.196G>A, NM_001709.4:c.196G>A, NM_170731.4:c.220G>A, NM_170732.4:c.196G>A, NM_170733.3:c.196G>A, NM_170734.3:c.241G>A, NM_170735.5:c.196G>A, NP_001137277.1:p.Val66Met, NP_001137278.1:p.Val66Met, NP_001137279.1:p.Val66Met, NP_001137280.1:p.Val66Met, NP_001137281.1:p.Val95Met, NP_001137282.1:p.Val148Met, NP_001137283.1:p.Val66Met, NP_001137284.1:p.Val66Met, NP_001137285.1:p.Val66Met, NP_001137286.1:p.Val66Met, NP_001137288.1:p.Val66Met, NP_001700.2:p.Val66Met, NP_733927.1:p.Val74Met, NP_733928.1:p.Val66Met, NP_733929.1:p.Val66Met, NP_733930.1:p.Val81Met, NP_733931.1:p.Val66Met, NR_002832.2:n.503C>T, NR_033312.1:n.434C>T, NR_033313.1:n.434C>T, NR_033314.1:n.503C>T, NR_033315.1:n.434C>T, XM_005253060.1:c.442G>A, XM_011520280.1:c.442G>A, XP_005253117.1:p.Val148Met, XP_011518582.1:p.Val148Met, XR_242807.1:n.355C>T, XR_242808.1:n.352C>T, XR_242809.1:n.224-802C>T, rs16917222, rs17855547, rs3829232, rs386602118, rs60760775
C > -
C > A
SNP
V66M
No VIP available CA No Variant Annotations available
rs6277 NC_000011.10:g.113412737G>A, NC_000011.9:g.113283459G>A, NG_008841.1:g.67543C>T, NM_000795.3:c.957C>T, NM_016574.3:c.870C>T, NP_000786.1:p.Pro319=, NP_057658.2:p.Pro290=, XM_005271425.1:c.957C>T, XM_005271426.1:c.954C>T, XP_005271482.1:p.Pro319=, XP_005271483.1:p.Pro318=, rs1071576, rs1075651, rs17413837, rs3189090
G > A
SNP
P319P
No VIP available No Clinical Annotations available VA
rs6280 NC_000003.11:g.113890815C>T, NC_000003.12:g.114171968C>T, NG_008842.2:g.32440G>A, NM_000796.5:c.25G>A, NM_001282563.2:c.25G>A, NM_001290809.1:c.25G>A, NM_033663.5:c.25G>A, NP_000787.2:p.Gly9Ser, NP_001269492.1:p.Gly9Ser, NP_001277738.1:p.Gly9Ser, NP_387512.3:p.Gly9Ser, XM_005247170.1:c.25G>A, XM_005247171.1:c.25G>A, XM_011512510.1:c.25G>A, XM_011512511.1:c.25G>A, XM_011512512.1:c.25G>A, XP_005247227.1:p.Gly9Ser, XP_005247228.1:p.Gly9Ser, XP_011510812.1:p.Gly9Ser, XP_011510813.1:p.Gly9Ser, XP_011510814.1:p.Gly9Ser, rs117481259, rs324025, rs52792556, rs59703514
C > T
SNP
G9S
No VIP available CA VA
rs6311 NC_000013.10:g.47471478C>T, NC_000013.11:g.46897343C>T, NG_013011.1:g.4692G>A, NM_000621.4:c.-998G>A, NM_001165947.2:c.-510G>A, rs36213154, rs61203218
C > T
SNP
No VIP available No Clinical Annotations available VA
rs6313 NC_000013.10:g.47469940G>A, NC_000013.11:g.46895805G>A, NG_013011.1:g.6230C>T, NM_000621.4:c.102C>T, NM_001165947.2:c.160+869C>T, NP_000612.1:p.Ser34=, rs17367493, rs3742280, rs386602276, rs57425741
G > A
SNP
S34S
No VIP available No Clinical Annotations available VA
rs6318 NC_000023.10:g.113965735G=, NC_000023.10:g.113965735G>C, NC_000023.11:g.114731326C=, NC_000023.11:g.114731326C>G, NG_012082.2:g.152242G=, NG_012082.2:g.152242G>C, NM_000868.3:c.68G=, NM_000868.3:c.68G>C, NM_001256760.2:c.68G=, NM_001256760.2:c.68G>C, NM_001256761.2:c.68G=, NM_001256761.2:c.68G>C, NP_000859.1:p.Cys23=, NP_000859.1:p.Cys23Ser, NP_001243689.1:p.Cys23=, NP_001243689.1:p.Cys23Ser, NP_001243690.1:p.Cys23=, NP_001243690.1:p.Cys23Ser, NW_004070891.1:g.400128C=, NW_004070891.1:g.400128C>G, XR_944300.1:n.209-550C>G, XR_944300.1:n.209-550G>C, XR_944301.1:n.209-550C>G, XR_944301.1:n.209-550G>C
G > C
SNP
C23S
No VIP available CA VA
rs6465084 NC_000007.13:g.86403475A>G, NC_000007.14:g.86774159A>G, NM_000840.2:c.468+8546A>G, XM_005250286.1:c.468+8546A>G, XM_005250287.1:c.85-12102A>G, XM_005250288.1:c.468+8546A>G, XM_005250289.1:c.101-64680A>G, XM_005250290.1:c.468+8546A>G, XM_011516088.1:c.468+8546A>G, XM_011516089.1:c.468+8546A>G, XM_011516090.1:c.468+8546A>G, XR_927721.1:n.2616T>C, rs10385355
A > G
SNP
No VIP available No Clinical Annotations available VA
rs649446 NC_000011.10:g.73984800C>T, NC_000011.9:g.73695845C>T, NG_011478.1:g.3045G>A, NM_003355.2:c.-2336G>A, rs60982407
C > T
SNP
No VIP available No Clinical Annotations available VA
rs655717 NC_000011.10:g.73973170A>G, NC_000011.9:g.73684215A>G, NG_011478.1:g.14675T>C, rs17244706, rs386603512, rs58444401
A > G
SNP
No VIP available No Clinical Annotations available VA
rs659366 NC_000011.10:g.73983709C>T, NC_000011.9:g.73694754C>T, NG_011478.1:g.4136G>A, NM_003355.2:c.-1245G>A, rs17174147, rs3829934, rs52801495, rs59575906
C > T
SNP
No VIP available No Clinical Annotations available VA
rs660339 NC_000011.10:g.73978059G>A, NC_000011.9:g.73689104G>A, NG_011478.1:g.9786C>T, NM_003355.2:c.164C>T, NP_003346.2:p.Ala55Val, rs1050841, rs117907410, rs17848359, rs2228495, rs59652865
G > A
SNP
A55V
No VIP available No Clinical Annotations available VA
rs668514 NC_000011.10:g.73995469C>T, NC_000011.9:g.73706514C>T, NG_024386.1:g.813G>A, XR_950298.1:n.1203C>T, rs59750531
C > A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs6773957 NC_000003.11:g.186573705A>G, NC_000003.12:g.186855916A>G, NG_021140.1:g.18243A>G, NM_001177800.1:c.*1212A>G, NM_004797.3:c.*1212A>G, NR_046662.1:n.208T>C, XM_011513324.1:c.*1212A>G, rs17846870, rs56725722, rs60603726
A > -
A > C
SNP
No VIP available No Clinical Annotations available VA
rs6782475 NC_000003.11:g.12471330T>G, NC_000003.12:g.12429831T>G, NG_011749.1:g.146982T>G, NM_005037.5:c.1187-4067T>G, NM_015869.4:c.1271-4067T>G, NM_138711.3:c.1187-4067T>G, NM_138712.3:c.1187-4067T>G, XM_011533840.1:c.1187-4067T>G, XM_011533841.1:c.1187-4067T>G, XM_011533842.1:c.1270+12677T>G, XM_011533843.1:c.820-4067T>G, XM_011533844.1:c.736-4067T>G
T > G
SNP
No VIP available CA VA
rs6977820 NC_000007.13:g.154072020T>C, NC_000007.14:g.154374935T>C, NG_033878.1:g.492602T>C, NM_001039350.2:c.52-71279T>C, NM_001290252.1:c.57+69384T>C, NM_001290253.1:c.244-71279T>C, NM_001936.4:c.57+69384T>C, NM_130797.3:c.244-71279T>C, XM_011515865.1:c.52-71279T>C, rs57278084
T > C
SNP
No VIP available No Clinical Annotations available VA
rs709149 NC_000003.11:g.12450354G>A, NC_000003.12:g.12408855G>A, NG_011749.1:g.126006G>A, NM_005037.5:c.735+2774G>A, NM_015869.4:c.819+2774G>A, NM_138711.3:c.735+2774G>A, NM_138712.3:c.735+2774G>A, XM_011533840.1:c.735+2774G>A, XM_011533841.1:c.735+2774G>A, XM_011533842.1:c.819+2774G>A, XM_011533843.1:c.819+2774G>A, XM_011533844.1:c.735+2774G>A, rs117451483, rs1699336, rs3773355, rs56885526
G > A
G > T
SNP
No VIP available No Clinical Annotations available VA
rs7295250 NC_000012.11:g.2776943T>C, NC_000012.12:g.2667777T>C, NG_008801.2:g.701992T>C, NM_000719.6:c.4623+995T>C, NM_001129827.1:c.4767+995T>C, NM_001129829.1:c.4689+995T>C, NM_001129830.1:c.4623+995T>C, NM_001129830.2:c.4623+995T>C, NM_001129831.1:c.4707+995T>C, NM_001129832.1:c.4683+995T>C, NM_001129833.1:c.4623+995T>C, NM_001129834.1:c.4623+995T>C, NM_001129835.1:c.4623+995T>C, NM_001129836.1:c.4674+995T>C, NM_001129837.1:c.4590+995T>C, NM_001129838.1:c.4590+995T>C, NM_001129839.1:c.4584+995T>C, NM_001129840.1:c.4623+995T>C, NM_001129841.1:c.4623+995T>C, NM_001129842.1:c.4623+995T>C, NM_001129843.1:c.4623+995T>C, NM_001129844.1:c.4614+995T>C, NM_001129846.1:c.4590+995T>C, NM_001167623.1:c.4623+995T>C, NM_001167624.2:c.4623+995T>C, NM_001167625.1:c.4590+995T>C, NM_199460.3:c.4767+995T>C, XM_005253765.1:c.4917+995T>C, XM_005253766.1:c.4776+995T>C, XM_005253767.1:c.4599+995T>C, XM_005253768.1:c.4776+995T>C, XM_005253769.1:c.4698+995T>C, XM_005253770.1:c.4632+995T>C, XM_005253771.1:c.4632+995T>C, XM_005253772.1:c.4716+995T>C, XM_005253773.1:c.4692+995T>C, XM_005253774.1:c.4632+995T>C, XM_005253775.1:c.4632+995T>C, XM_005253776.1:c.4632+995T>C, XM_005253777.1:c.4683+995T>C, XM_005253778.1:c.4599+995T>C, XM_005253779.1:c.4599+995T>C, XM_005253780.1:c.4593+995T>C, XM_005253781.1:c.4632+995T>C, XM_005253782.1:c.4632+995T>C, XM_005253783.1:c.4632+995T>C, XM_005253784.1:c.4632+995T>C, XM_005253785.1:c.4632+995T>C, XM_005253786.1:c.4623+995T>C, XM_005253787.1:c.4599+995T>C, XM_005253788.1:c.2529+995T>C, XM_006719017.1:c.4713+995T>C, XM_011521017.1:c.3867+995T>C, XM_011521018.1:c.3312+995T>C, XM_011521019.1:c.1422+995T>C, XM_011521020.1:c.4788+995T>C, XM_011521021.1:c.4623+995T>C, XM_011521022.1:c.4623+995T>C, XM_011521023.1:c.4698+995T>C, rs17761221, rs60758963
T > C
SNP
No VIP available No Clinical Annotations available VA
rs7336345 NC_000013.10:g.83144007C>A, NC_000013.11:g.82569872C>A, rs112105982, rs61396868, rs9318883
C > A
SNP
No VIP available No Clinical Annotations available VA
rs7566605 NC_000002.11:g.118836025C>G, NC_000002.12:g.118078449C>G, XM_011512305.1:c.697-917G>C, rs61203538
C > G
SNP
No VIP available No Clinical Annotations available VA
rs7620165 NC_000003.11:g.12344441A>G, NC_000003.12:g.12302942A>G, NG_011749.1:g.20093A>G, NM_005037.5:c.-3+14922A>G, NM_138711.3:c.-76-9438A>G, NM_138712.3:c.-76-9438A>G, XM_011533841.1:c.-3+13808A>G, XM_011533844.1:c.-76-9438A>G, rs60196309
A > G
SNP
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
No VIP available No Clinical Annotations available VA
rs7627128 NC_000003.11:g.186568799C>A, NC_000003.12:g.186851010C>A, NG_021140.1:g.13337C>A, NM_001177800.1:c.-8-2041C>A, NM_004797.3:c.-8-2041C>A, XM_011513324.1:c.-124-96C>A, rs36219757, rs61337351
C > A
SNP
No VIP available No Clinical Annotations available VA
rs7645903 NC_000003.11:g.12463826A>T, NC_000003.12:g.12422327A>T, NG_011749.1:g.139478A>T, NM_005037.5:c.1186+5173A>T, NM_015869.4:c.1270+5173A>T, NM_138711.3:c.1186+5173A>T, NM_138712.3:c.1186+5173A>T, XM_011533840.1:c.1186+5173A>T, XM_011533841.1:c.1186+5173A>T, XM_011533842.1:c.1270+5173A>T, XM_011533843.1:c.820-11571A>T, XM_011533844.1:c.736-11571A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs7650895 NC_000003.11:g.12475162A>C, NC_000003.12:g.12433663A>C, NG_011749.1:g.150814A>C, NM_005037.5:c.1187-235A>C, NM_015869.4:c.1271-235A>C, NM_138711.3:c.1187-235A>C, NM_138712.3:c.1187-235A>C, XM_011533840.1:c.1187-235A>C, XM_011533841.1:c.1187-235A>C, XM_011533842.1:c.1270+16509A>C, XM_011533843.1:c.820-235A>C, XM_011533844.1:c.736-235A>C, rs57354505
A > C
SNP
No VIP available CA VA
rs7799039 NC_000007.13:g.127878783G>A, NC_000007.14:g.128238730G>A, NG_007450.1:g.2453G>A, XR_927945.1:n.-1932C>T
G > A
SNP
No VIP available No Clinical Annotations available VA
rs8050136 NC_000016.10:g.53782363C>A, NC_000016.9:g.53816275C>A, NG_012969.1:g.83401C>A, NM_001080432.2:c.46-27777C>A, XM_011523313.1:c.46-27777C>A, XM_011523314.1:c.46-27777C>A, XM_011523315.1:c.46-27777C>A, XM_011523316.1:c.46-27777C>A, rs17817527, rs57095495
C > A
SNP
No VIP available No Clinical Annotations available VA
rs806374 NC_000006.11:g.88857320T>C, NC_000006.12:g.88147601T>C, NM_001160226.1:c.-64+63A>G, NM_001160258.1:c.-64+63A>G, NM_001160259.1:c.-63-2264A>G, NM_016083.4:c.-63-2264A>G, XM_005248649.1:c.-63-2264A>G, XM_005248650.1:c.-64+15A>G, XM_005248650.3:c.-64+15A>G, XM_005248651.1:c.-63-2264A>G, XM_005248652.1:c.-79-2264A>G, XM_006715330.2:c.-63-2264A>G, XM_011535424.1:c.-64+15A>G, XM_011535425.1:c.-64+15A>G, XM_011535426.1:c.-64+15A>G, XM_011535427.1:c.-64+15A>G, XM_011535428.1:c.-63-2264A>G, rs1744430, rs57399011, rs58915827
T > C
SNP
No VIP available No Clinical Annotations available VA
rs822391 NC_000003.11:g.186563803C>T, NC_000003.12:g.186846014C>T, NG_021140.1:g.8341C>T, NM_001177800.1:c.-9+407C>T, NM_004797.3:c.-9+3265C>T, XM_011513324.1:c.-125+3265C>T, rs59135918
C > T
SNP
No VIP available No Clinical Annotations available VA
rs822393 NC_000003.11:g.186566326C>T, NC_000003.12:g.186848537C>T, NG_021140.1:g.10864C>T, NM_001177800.1:c.-9+2930C>T, NM_004797.3:c.-8-4514C>T, XM_011513324.1:c.-124-2569C>T, rs1656949
C > T
SNP
No VIP available No Clinical Annotations available VA
rs822396 NC_000003.11:g.186566877G>A, NC_000003.12:g.186849088G>A, NG_021140.1:g.11415G>A, NM_001177800.1:c.-9+3481G>A, NM_004797.3:c.-8-3963G>A, XM_011513324.1:c.-124-2018G>A, rs1656950, rs59131134
G > A
SNP
No VIP available CA VA
rs878949 NC_000001.10:g.22227091T>C, NC_000001.11:g.21900598T>C, NG_016740.1:g.41660A>G, NM_001291860.1:c.64-4288A>G, NM_005529.6:c.64-4288A>G, XM_005245859.1:c.64-4288A>G, XM_005245860.1:c.64-4288A>G, XM_005245861.1:c.64-4288A>G, XM_005245862.1:c.64-4288A>G, XM_005245863.1:c.64-4288A>G, XM_005245865.1:c.64-4288A>G, XM_006710594.2:c.64-4288A>G, XM_006710595.2:c.64-4288A>G, XM_006710596.2:c.64-4288A>G, XM_006710597.2:c.64-4288A>G, XM_011541317.1:c.64-4288A>G, XM_011541318.1:c.64-4288A>G, XM_011541319.1:c.64-4288A>G, XM_011541320.1:c.64-4288A>G, XM_011541321.1:c.64-4288A>G, XM_011541322.1:c.64-4288A>G, rs58418332
T > C
SNP
No VIP available CA VA
rs9346455 NC_000006.11:g.71991816T>G, NC_000006.12:g.71282113T>G, XR_942680.1:n.653+1661A>C, XR_942681.1:n.455+28183A>C, rs61340169
T > G
SNP
No VIP available No Clinical Annotations available VA
rs9395206 NC_000006.11:g.46638422T>A, NC_000006.12:g.46670685T>A, NM_001204051.1:c.798-441T>A, NM_001204052.1:c.704+1892T>A, NM_004277.4:c.798-441T>A, NR_134642.1:n.235-100A>T, NR_134643.1:n.233-100A>T, NR_134644.1:n.160-100A>T, XM_005249483.1:c.798-441T>A, XM_005249483.2:c.798-441T>A, XM_005249484.1:c.654-441T>A, XM_005249485.1:c.483-441T>A, XR_241952.1:n.952+1892T>A, XR_242029.1:n.252-100A>T, XR_242029.2:n.235-100A>T, XR_242030.1:n.82-100A>T, XR_427858.1:n.1046-441T>A, rs17216750, rs59354211
T > A
SNP
No VIP available No Clinical Annotations available VA
rs951436 NC_000001.10:g.163033342A>C, NC_000001.11:g.163063552A>C, rs36214195, rs61316963
A > C
SNP
No VIP available CA No Variant Annotations available
rs951439 NC_000001.10:g.163033691C>T, NC_000001.11:g.163063901C>T, NG_023312.1:g.296C>T, rs36214199, rs386623110, rs52799590, rs57153444
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9852 NC_000004.11:g.38139024C>T, NC_000004.12:g.38137403C>T, NM_001253912.1:c.*68C>T, NM_001253913.1:c.*68C>T, NM_001253914.1:c.*68C>T, NM_001253915.1:c.*68C>T, NM_015173.3:c.*68C>T, XM_005262646.1:c.*68C>T, XM_005262647.1:c.*68C>T, XM_005262648.1:c.*68C>T, XM_005262649.1:c.*68C>T, XM_005262650.1:c.*68C>T, XM_005262651.1:c.*68C>T, XM_006714001.1:c.*68C>T, XM_011513659.1:c.*68C>T, XM_011513660.1:c.*68C>T, XM_011513661.1:c.*68C>T, XM_011513662.1:c.*68C>T, XM_011513663.1:c.*68C>T, XM_011513664.1:c.*68C>T, XM_011513665.1:c.*68C>T, XM_011513666.1:c.*68C>T, XM_011513667.1:c.*68C>T, XM_011513669.1:c.*68C>T, XM_011513670.1:c.*68C>T, rs17580009, rs3186425, rs61627288
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9882205 NC_000003.11:g.186570398G>A, NC_000003.12:g.186852609G>A, NG_021140.1:g.14936G>A, NM_001177800.1:c.-8-442G>A, NM_004797.3:c.-8-442G>A, NR_046662.1:n.2720C>T, XM_011513324.1:c.-8-442G>A, rs36219754, rs386421037
G > C
G > T
SNP
No VIP available No Clinical Annotations available VA
rs9930506 NC_000016.10:g.53796553A>G, NC_000016.9:g.53830465A>G, NG_012969.1:g.97591A>G, NM_001080432.2:c.46-13587A>G, XM_011523313.1:c.46-13587A>G, XM_011523314.1:c.46-13587A>G, XM_011523315.1:c.46-13587A>G, XM_011523316.1:c.46-13587A>G, rs58569962
A > G
SNP
No VIP available No Clinical Annotations available VA
rs9939609 NC_000016.10:g.53786615T>A, NC_000016.9:g.53820527T>A, NG_012969.1:g.87653T>A, NM_001080432.2:c.46-23525T>A, XM_011523313.1:c.46-23525T>A, XM_011523314.1:c.46-23525T>A, XM_011523315.1:c.46-23525T>A, XM_011523316.1:c.46-23525T>A, rs17817682, rs58374961, rs61046791
T > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACACA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACACB
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACE
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ADCY2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADH1B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADH1C
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADH4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ADIPOQ
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRA1A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRA1D
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRA2A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRB3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AKAP6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AKAP7
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AKAP9
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ALDH2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ANGPTL4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ANK2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ANKK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APLP2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APOE
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APP
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ATP2A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AUTS2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AVPR1B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BACE1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
BDNF
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
BDNF-AS
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CACNA1C
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CACNB2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CALCR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CALR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CAV3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CCL2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRM2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CHRM4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRNA3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRNA4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRNA5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRNB2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CHRNB4
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CLCN6
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CNR1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
COMT
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP1A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2E1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP39A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYSLTR1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DBH
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DNAJB13
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DPP6
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD1
DRD2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DTNBP1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EN1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EPAS1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
FKBP5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
FOSB
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
FPR1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FTO
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GABRA2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GABRB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GABRB3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GABRE
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GABRG2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GABRG3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GATA3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GCG
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GCGR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GHSR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GIPR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GLS2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GNB3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GPD1L
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GPR35
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIA2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIA3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIK2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIK3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIK4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIN1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIN3B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRM2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GRM3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRM5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSK3B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSTM1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSTT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GZMA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HCG9
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HMGCR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HRH3
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HSPG2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HTR1A
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HTR2A
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HTR2C
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HTR3A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HTR3B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HTR3E
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
IBA57
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL1B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
INSIG1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
INSIG2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IREB2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
JAKMIP1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
JPH2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
JPH3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCND3
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
KCNE1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNE2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNH2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNJ2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNJ5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNN3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KCNQ1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KEL
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KISS1R
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LDLR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LEP
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LEPR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LHX5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LMX1B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAOA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAOB
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAP2K1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAPT
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAS1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MC4R
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MCHR1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MCHR2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MTHFR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NAT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NEFM
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NGF
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NMUR2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NOS1AP
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NOS3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NOTCH4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NPAS4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NPY
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NPY1R
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NR4A2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
NRG1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
NRXN1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NRXN3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NTRK2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NUBPL
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRD1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRM1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OXTR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2RX1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2RX6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2RY1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2RY14
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PARK2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PI4KA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PLA2G4B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PNMT
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PPARG
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PPP2R3A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PRLR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PSMA4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PTGFR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RAI1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RELN
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
RGS2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
RGS4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RPL39
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RPP21
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RYR2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
S1PR5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SCG2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SCN4B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SCN5A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SCTR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC17A6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC17A7
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC18A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC1A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC1A4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC22A23
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC25A14
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC25A27
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC6A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC6A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC6A4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SMYD3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SNTA1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SOD2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SSTR5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SULT1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SULT1A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TBC1D1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TBXA2R
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TDRD6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TH
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TMED10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TPH1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TPH2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UCP2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UCP3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT2B17
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
WDR18
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
WNT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
XBP1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ZFHX3
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ZNF804A
No related drugs are available.

Curated Information ?

Publications related to antipsychotics: 157

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016. Lanning Rachel K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatria Danubina. 2016. Terzić Tea, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. Journal of clinical psychopharmacology. 2016. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations. Molecular genetics & genomic medicine. 2016. Jajodia Ajay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage. Pharmacogenomics. 2016. Hettige Nuwan C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents. International journal of endocrinology. 2016. Dos Santos-Júnior Amilton, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. The pharmacogenomics journal. 2015. Brandl E J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes. Pharmacogenetics and genomics. 2015. Creta Elia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children. The pharmacogenomics journal. 2015. Cote A T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology. 2015. Bishop Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of genetic variation across IL-1beta, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2015. Fonseka Trehani M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2014. Kaur Harpreet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics. 2015. Devlin Angela M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014. Jenkins Aaron, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of psychiatric research. 2014. Kao A C C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry research. 2014. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics. 2014. Gaedigk Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 2014. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC medicine. 2014. Salloum Naji C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. Neuropsychobiology. 2014. Shing Emily C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The association between CYP2D6 genotype and switching antipsychotic medication to clozapine. European journal of clinical pharmacology. 2013. Gregoor Jochem G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of psychiatric research. 2013. Zai Clement C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2013. Czerwensky Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenetics and genomics. 2013. Roke Yvette, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophrenia research. 2013. Scarr Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophrenia research. 2013. Zhang Jian-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human psychopharmacology. 2013. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. Journal of clinical psychopharmacology. 2013. Czerwensky Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Translational psychiatry. 2013. Nurmi E L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics. 2012. Mas Sergi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry. 2012. Houston John P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics. 2012. Vijayan Neetha N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics. 2012. Kuzman Martina Rojnic, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European archives of psychiatry and clinical neuroscience. 2012. Crisafulli Concetta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. European archives of psychiatry and clinical neuroscience. 2012. Mössner Rainald, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. The pharmacogenomics journal. 2012. Lott S A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. The pharmacogenomics journal. 2012. Chowdhury N I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro endocrinology letters. 2012. Barteček Richard, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation. Cardiovascular genetics. 2011. Kääb Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011. Zhang Xiang Rong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. The pharmacogenomics journal. 2011. Tanaka S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. The pharmacogenomics journal. 2011. Greenbaum L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. The pharmacogenomics journal. 2011. Ono S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011. Gregoor Jochem G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics. 2011. Hill Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International journal of clinical pharmacy. 2011. Wilffert Bob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia. Pharmacogenomics. 2011. Mouaffak Fayçal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. The pharmacogenomics journal. 2011. Fleeman N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. The pharmacogenomics journal. 2011. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. Journal of child and adolescent psychopharmacology. 2010. Hoekstra Pieter J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010. Sicard Michelle N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2010. Aberg K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. 2010. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. The pharmacogenomics journal. 2010. Liou Y-J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: dopamine receptor D2. Pharmacogenetics and genomics. 2010. Mi Huaiyu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. The pharmacogenomics journal. 2010. Risselada A J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug and alcohol dependence. 2010. Gandhi Kunal K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. The American journal of psychiatry. 2010. Zhang Jian-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics and genomics. 2010. Hong Chen-Jee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Human psychopharmacology. 2010. Tiwari Arun K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry research. 2010. Vázquez-Bourgon Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. The pharmacogenomics journal. 2010. Liu Y-R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The pharmacogenomics journal. 2010. Laika B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatric genetics. 2009. Calarge Chadi A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The pharmacogenomics journal. 2009. Gassó P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and genomics. 2009. Schuhmacher Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting age-specific dosing of antipsychotics. Clinical pharmacology and therapeutics. 2009. Uchida H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. The pharmacogenomics journal. 2009. Godlewska B R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. 2009. Calarge Chadi A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. The pharmacogenomics journal. 2009. Greenbaum L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. 2009. Shen Yu-Chih, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Molecular psychiatry. 2009. Le Hellard S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics. 2009. Gupta Meenal, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. Journal of clinical psychopharmacology. 2009. Mulder Hans, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. The pharmacogenomics journal. 2009. Popp J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008. Ikeda Masashi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Model-based gene selection shows engrailed 1 is associated with antipsychotic response. Pharmacogenetics and genomics. 2008. Webb Bradley Todd, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Progress in neuro-psychopharmacology & biological psychiatry. 2008. Yasui-Furukori Norio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clinical and experimental pharmacology & physiology. 2008. Crescenti Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics. 2008. Kohlrausch Fabiana B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenetics and genomics. 2008. Xu Ming-Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics. 2008. Mill Jonathan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya journal of medical science. 2008. Ji Xiaofei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 phenotype prediction from genotype: which system is the best?. Clinical pharmacology and therapeutics. 2008. Kirchheiner J. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological psychiatry. 2008. Campbell Daniel B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia research. 2008. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia research. 2008. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. The pharmacogenomics journal. 2007. Molero P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Human psychopharmacology. 2007. De Luca Vincenzo, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Xing Qinghe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. The pharmacogenomics journal. 2007. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. The pharmacogenomics journal. 2007. Mulder H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular psychiatry. 2007. Zai C C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA and cell biology. 2007. Boke Omer, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. Journal of clinical psychopharmacology. 2007. Mulder Hans, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2007. Tay Joshua K X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. The pharmacogenomics journal. 2007. Theisen F M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Strous Rael D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Journal of psychopharmacology (Oxford, England). 2006. Plesnicar Blanka Kores, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.). 2006. Roberson Erik D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). 2006. Kampman O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. Journal of clinical psychopharmacology. 2006. Nolan Karen A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert review of molecular diagnostics. 2006. de Leon Jose. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Risperidone-related weight gain: genetic and nongenetic predictors. Journal of clinical psychopharmacology. 2006. Lane Hsien-Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta pharmacologica Sinica. 2006. Fu Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenetics and genomics. 2006. Liou Ying-Jay, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American journal of psychiatry. 2006. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. The pharmacogenomics journal. 2006. Davies M A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005. Hwang Rudi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2005. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience letters. 2005. Wu Shengnan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenetics and genomics. 2005. Patsopoulos Nikolaos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. The pharmacogenomics journal. 2005. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological psychiatry. 2004. Weickert Thomas W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. The American journal of psychiatry. 2004. Bertolino Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British journal of psychiatry : the journal of mental science. 2004. Young Ross McD, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics. 2004. Anttila Sami, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Therapeutic drug monitoring. 2004. Baumann P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology. 2004. Liou Ying-Jay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. Journal of clinical psychopharmacology. 2003. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatric genetics. 2003. Inada Toshiya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Inada Toshiya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2003. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy. 2002. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. The pharmacogenomics journal. 2002. Nikoloff D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. American journal of medical genetics. 2001. Schulze T G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001. Suzuki A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. European journal of clinical pharmacology. 2000. Scordo M G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular psychiatry. 2000. Basile V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Molecular psychiatry. 2000. Kaiser R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry research. 1999. Ohmori, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1999. Basile V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. International clinical psychopharmacology. 1999. Naranjo C A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. Journal of psychiatry & neuroscience : JPN. 1999. Joober R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998. Arranz M J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry research. 1998. Ohara K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia research. 1998. Kapitany T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophrenia research. 1998. Ohmori O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology. 1997. Andreassen O A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular psychiatry. 1997. Steen V M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. The British journal of psychiatry : the journal of mental science. 1997. Armstrong M, et al. PubMed

Clinical Trials

These are trials that mention antipsychotics and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.